Recurrent Melanoma Withdrawn Phase 2 Trials for Ipilimumab (DB06186)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03220009Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal MelanomaTreatment